1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Delaware >
  6. Boston Therapeutics Acquires CureDM

M&A Deal Summary

Boston Therapeutics Acquires CureDM

On February 13, 2018, Boston Therapeutics acquired life science company CureDM

Acquisition Highlights
  • This is Boston Therapeutics’ 1st transaction in the Life Science sector.
  • This is Boston Therapeutics’ 1st transaction in the United States.
  • This is Boston Therapeutics’ 1st transaction in Delaware.

M&A Deal Summary
Date 2018-02-13
Target CureDM
Sector Life Science
Buyer(s) Boston Therapeutics
Deal Type Add-on Acquisition

Target

CureDM

Wilmington, Delaware, United States
CureDM, Inc. is a clinical development of the novel peptide therapeutic, HIP2B, for the treatment of type 1 and type 2 diabetes. CureDM is based in Wilmington, Delaware.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Boston Therapeutics

Lawrence, Massachusetts, United States
Category Company
Sector Life Science
Revenue 99M USD (2015)
DESCRIPTION

Boston Therapeutics, Inc. is a designer, developer and commercialization of compounds, such as investigational BTI-320, to treat diabetes and diabetes related complications. Boston Therapeutics is based in Lawrence, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: Delaware M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2018 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal